CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 6 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-25 | Carter Laura Chief Scientific Officer | Sale | −2,377 | $12.25 | $29K | 95,306 |
| 2021-10-25 | Aranda Richard Chief Medical Officer | Sale | −2,377 | $12.25 | $29K | 217,432 |
| 2021-09-16 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2021-06-30 | Carter Laura Chief Scientific Officer | Grant or award | +25,000 | 97,683 | ||
| 2021-06-21 | Aranda Richard Chief Medical Officer | Grant or award | +15,000 | 219,809 | ||
| 2021-06-21 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2021-06-10 | Milligan Sandra Director | Grant or award · Stock Option (Right to Buy) | +47,000 | 47,000 | ||
| 2021-06-09 | Bilenker Joshua H. Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-06-09 | Burow Kristina Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-06-09 | Daniel Thomas O Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-06-09 | GALA RENEE D Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-06-09 | Cox Russell J. Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-05-03 | Carter Laura Chief Scientific Officer | Grant or award | +10,820 | 72,683 | ||
| 2021-05-03 | Carter Laura Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +31,750 | 31,750 | ||
| 2021-04-16 | Peterson Caryn EVP, Regulatory Affairs | Grant or award | +10,820 | 74,828 | ||
| 2021-04-16 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +31,750 | 31,750 | ||
| 2021-03-23 | Salter-Cid Luisa Chief Scientific Officer | Sale | −5,491 | $9.48 | $52K | 206,065 |
| 2021-03-23 | Giraudo Bryan Chief Financial Officer | Sale | −5,490 | $9.48 | $52K | 109,889 |
| 2021-03-23 | Christian Waage EVP & General Counsel | Sale | −5,490 | $9.48 | $52K | 588,199 |
| 2021-02-25 | Hasnain Faheem President & CEO | Grant or award | +162,500 | 162,500 |
Page 16 of 21 · 401 trades